CTRI/2011/07/001914已完成3 期
A Randomized, Prospective, Open label, Parallel group, Comparative,Multi-Center Study to Determine the Safety and Efficacy of Truteksdevice Multi Acting Nasal Particle Blocker (MAPB) as a PreventiveTreatment for Cold and Flu. - Nil
Trutek Corp0 个研究点目标入组 600 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male and Female subjects, 18 to70 years (inclusive) of age.
- •2. Willing to sign the written informed consent form.
- •3. Willingness to comply with the test procedure.
排除标准
- •Exclusion Criteria:
- •Subjects who are more at risk for cold and/or flu or cold and/or flu complications than the general population such as serious respiratory problems, immune system disorders, and serious heart problems or individuals with other serious health problems may be excluded from the study if, at the discretion of the Principal Investigator, their participation would constitute a threat to their health.
- •Subjects who report any two or more of the cold and/or flu symptoms in the past seven days with at least one significantly worsening in the past 1 to 4 days may be construed to have acquired cold and/or flu and excluded from the study.
- •1. Subjects who have planned travel outside study area for a substantial portion of the study period.
- •2. Subjects who have gotten the flu shot within the last twelve months will not be allowed to participate.
- •3. Pregnant or nursing subjects. (There are, however, no risks for pregnant women and fetus by use, as directed, of the test article.)
- •4. Subjects who have had a life-threatening health emergency within the last six months will not be allowed to participate.
- •5. Subjects who have received any investigational product within 30 days of enrollment.
- •6. Subjects who have history of allergic rhinitis expected to occur during the study period.
- •7. Subjects who have used any antiviral influenza medications within 2 weeks of screening or during the study period.
- •8. Subjects who have documented infection within two weeks prior to screening.
- •9. Subjects who have any chronic medical condition treated within 3 months prior to screening.
- •10. Subjects who have any systemic immunologic or immunosuppressive diseases.
- •11. Subjects who are scheduled for surgery during the study period.
研究者
相似试验
已完成
不适用
A study to Evaluate the Safety and Efficacy of Herbal /Nutraceutical Oral Capsule and Herbal / Nutraceutical Rectal Medication Combination in Improving the Gut Health of Patients with Type 2 Diabetes Having Chronic Kidney Disease (CKD).CTRI/2022/04/042052Arogyaseva Medical Academy of India AMAI80
尚未招募
不适用
Study of two anti-allergic drugs in allergic ConjunctivitisCTRI/2018/05/013792kempegowda institute of medical sciences
尚未招募
3 期
This is a Phase 3 Study to Evaluate the Efficacy, Safety, Immunogenicity and Pharmacokinetics of Proposed Trastuzumab Emtansine Biosimilar Compared with Kadcyla in HER2-positive Breast Cancer PatientsCTRI/2024/08/072580Intas Pharmaceuticals Limited
招募中
4 期
Immunogenicity and safety of Insulin in patients of Diabetes MellitusCTRI/2022/06/043563Wockhardt Ltd
进行中（未招募）
不适用
A Prospective, Open Label, Randomised, Parallel Group Trial Comparing the Effects of Highly Purified Menotrophin and Recombinant Follicle Stimulating Hormone (rFSH, Follitropin alpha) Administered Subcutaneoulsy to Subfertile Female Patients Undergoing IVF Using Antagonist Down-Regulation on Progesterone Serum Levels During the Follicular Phase and their Possible Use as Predictors for the Success Rate of Ongoing Pregnancies (PREDICT) - PREDICTEUCTR2010-019411-37-DEFERRING Arzneimittel GmbH